Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$4.73
EPS est.
$4.30
EPS surprise
+9.95%
1-day move
-1.34%
Vertex Pharmaceuticals reported an EPS that was slightly below expectations, which may have contributed to the stock's decline of 1.34%. The lack of revenue data and guidance updates leaves investors with limited insight into the company's future performance. Overall, the market reaction suggests some caution among investors following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.73 | $4.75 | +9.95% |
| Revenue | — | $3.2B | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases. With a market cap of $131 billion, it plays a significant role in the health care sector, particularly in treating genetic diseases like cystic fibrosis.
Last quarter
In Q1-2026, Vertex reported an EPS of $4.47, significantly surpassing analyst expectations. The stock reacted positively, gaining 1.40% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+16.95%
Avg 1-day reaction
+0.43%
Analysts are expecting Vertex to report strong earnings driven by solid sales of its existing therapies. The consensus EPS estimate of $4.75 suggests continued profitability.
Bull case
If Vertex exceeds the EPS estimate, it could indicate strong demand for its therapies and potentially lead to a stock price increase.
Bear case
A miss on EPS or revenue could raise concerns about market demand and the company's growth prospects, leading to a negative reaction in the stock.
Key metrics to watch
EPS
$4.75Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for shareholders.
Revenue
$3.2BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $4.75?
A higher EPS could signal strong operational performance and boost investor confidence.
Q2
What are the revenue figures compared to the consensus of $3.2B?
Revenue performance will indicate market demand for Vertex's therapies and its growth trajectory.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate Vertex's pipeline potential and the impact of new therapies on revenue growth.
Supporting evidence
Vertex has consistently beaten EPS estimates, indicating stronger operational performance than expected.
The options market is pricing a larger move than historical averages, suggesting heightened uncertainty.
Recent trends in patient demand for Vertex's therapies suggest a more robust growth outlook.
Key risk
If revenue falls below $3.1B, it could challenge the optimistic growth narrative.
Pre-commit to what would confirm each case.
The market is debating whether Vertex can maintain its strong performance amid increasing competition and market pressures.
Bull confirmed if
An EPS of $5.00 or higher would confirm strong demand and effective cost management.
Bear confirmed if
An EPS below $4.50 would raise concerns about the sustainability of growth.
What the market is pricing for the move.
Implied Move
±13.77%
Historical Avg
±0.8%
The options market is pricing in a significant potential move following the earnings report, indicating uncertainty among investors.
Options are pricing ±13.8% while VRTX has averaged ±0.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
19.6%
Smart-money positioning from the most recent 13F filings.
Institutional
97.99%
of float
Insider
0.21%
of float
Holders
2,428
institutions
Top Holders· as of Jun 2026
Capital World Investors
26,115,014 sh · $13.2B
10.29%
2.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Vertex beats expectations, history suggests a potential stock increase of around 0.69%, confirming strong market demand.
In line / cautious
If results are in line with expectations, the stock may see a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of about 2.03%, reflecting concerns about the company's growth prospects.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
24,109,373 sh · $12.2B
9.50%
0.6%
Capital Research Global Investors
19,490,637 sh · $9.9B
7.68%
-7.7%
Vanguard Capital Management LLC
16,580,713 sh · $8.4B
6.53%
0.4%
State Street Corporation
11,871,459 sh · $6.0B
4.68%
1.2%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 26, 2026 · disclosed Sep 5, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.